Cargando…
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy
Genomic alterations may make cancer cells more dependent than normal cells on mechanisms of proteostasis, including protein folding and degradation. This proposition is the basis for the clinical use of proteasome inhibitors to treat multiple myeloma and mantle cell lymphoma. However, proteasome inh...
Autor principal: | Deshaies, Raymond J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226866/ https://www.ncbi.nlm.nih.gov/pubmed/25385277 http://dx.doi.org/10.1186/s12915-014-0094-0 |
Ejemplares similares
-
Proteasome Activation to Combat Proteotoxicity
por: Jones, Corey L., et al.
Publicado: (2019) -
NEDDylation promotes nuclear protein aggregation and protects the Ubiquitin Proteasome System upon proteotoxic stress
por: Maghames, Chantal M., et al.
Publicado: (2018) -
Ribosomal proteins produced in excess are degraded by the ubiquitin–proteasome system
por: Sung, Min-Kyung, et al.
Publicado: (2016) -
Quantitative Cell-based Protein Degradation Assays to Identify and Classify Drugs That Target the Ubiquitin-Proteasome System
por: Chou, Tsui-Fen, et al.
Publicado: (2011) -
Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy
por: Aliabadi, Fatemeh, et al.
Publicado: (2021)